A clinical review: Covid19 and Dermatology

Abstract

On March 11, 2020, the World Health Organization(WHO) declared Corona Virus Disease-2019(COVID-19) as a pandemic disease caused by SARS-CoV-2. During the COVID-19 pandemic, the importance of dermatology practice in patient management has emerged. Skin involvement was rarely documented in the first reported case series. The reason for this has been shown to be that a complete dermatological examination can not be performed in cases. Over time, significantly higher rates of skin findings have been reported.The mechanism of skin lesions associated with COVID-19 is not yet clear. The most common view is that lymphocytic vasculitis caused by vascularly located viral particles and langerhans cell activation is caused by an immune response to infection leading to vasodilation and spongiosis.Keratinocytes are thought to be secondary targets.It has been emphasized that skin findings are encountered at rates varying between 2-20% in COVID-19 patients. Casas et al. performed the first prospective study to classify the skin manifestations of COVID-19 into five major groups, including pseudo-chilblains (19%), other vesicular eruptions (9%),maculopapuler eruption(47%),livedo or necrosis(6%) and urticarial lesions (19%).

Keywords

• COVID-19
• Dermatology
• Cutaneous Manifestations

References

1. 1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.
2. 2. Yang p, Wang X. COVID-19: a new challenge for human beings. Cellular & Molecular Immunology. 2020;17(5):555-557.
3. 3.Puliatti S, Eissa A, Eissa R et al. COVID-19 and urology: a comprehensive review of the literature. BJU Int 2020. Jun;125(6):7-14.
4. 4. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 51 11 March 2020. URL https://www. who.int/docs/default-source/coronaviruse/situation reports/20200311 10 (lastaccessed: 23 March 2020)
5. 5. Galvan Casas C, Catali A, Carretero Hernandez G. et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nation-wide consensus study in Spainwith 375 cases. Br J Dermatol. 2020;183(1):71-77.
6. 6.Gianotti R, Zerbi P, Dodiuk-Gad RP. Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy. J Dermatol Sci. 2020;98:141-3.
7. 7. Türsen Ü, Türsen B, Lotti T. Coronavirus-days ın dermatology. Dermatologic Therapy. 2020Jul;33(4):e13438. DOI: 10.1111/dth.13438.
8. 8. liu W, li H. Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020;10.26434.

9. 9. Topal İO, Güngör Ş, Topal Y, Kocatürk Göncü E. Perniyo: Bir olgu bildirimi ve ayırıcı tanıların gözden geçirilmesi. Okmeydanı Tıp Dergisi. 2016;32(4):230-233.
10. 10. Nirenberg MS, Herrera MDMR. Foot manifestations in a patient with COVID-19 and Epstein-Barr virus: A case study. Foot (Edinb). 2020 Jun 22:101707. doi: 10.1016/j.foot.2020.101707.
11. 11. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020;34(7):291-293. doi:10.1111/jdv.16526
12. 12. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13. doi:10.1016/j.trsl.2020.04.007
13. 13.Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J,et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol. 2020 May 8:10.1111/ced.14277. doi: 10.1111/ced.14277
14. 14. Llamas-Velasco M, Rodriguez-Jimenez P, Chicharro P et al. Reply to ‘Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients’: to consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. JAmAcad Dermatol 2020; https ://doi.org/10.1016/j.jaad.2020.04.180
15. 15. Mariyath OK, Samad KA, Devi K, Surya VS, Effeena MD, Ajina M. Atypical maculopapular rash as the initial sign of COVID-19:A case report from a COVID hospital. J Skin Sex Transm Dis, doi: 10.25259/JSSTD_46_2020
16. 16. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, etal. The EAACI/GA²LEN/EDF/WAO guideline for the definition,classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.
17. 17. Fayne R, Castillo DE, Sanchez N, et al. Dermatology consultation service at a large metropolitan hospital system serving minority populations. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16565
18. 18.van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(7):300-301.
19. 19. Royal Belgian Society of Dermatology and Venerology. EEM and Covid19; 2020.URL https://www.belgiandermatology.be/en/announcements/eem‐en‐covid‐19.